Epcoritamab

Epcoritamab (Epkinly in the US, Tepkinly in the EU) is a subcutaneous CD3xCD20 bispecific antibody from Genmab and AbbVie. It received FDA accelerated approval (BLA 761324, a Biologics License Application granted based on a surrogate endpoint with confirmatory trial required) in May 2023 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior lines [3]. NCT05578976 (EPCORE DLBCL-2) is the frontline gambit: a Phase 3 trial testing whether adding epcoritamab to R-CHOP - the chemoimmunotherapy backbone used since 2002 in newly diagnosed DLBCL - improves outcomes over R-CHOP alone, with PFS in IPI 3-5 (International Prognostic Index 3-5, identifying high-risk patients by age, stage, LDH, performance status, and extranodal sites) as the primary endpoint [5]. A positive readout would move epcoritamab from salvage into first-line use, expanding the addressable patient population by roughly 5-10x and validating CD20xCD3 bispecifics as a chemotherapy add-on rather than a single-agent salvage option. The competitive context just shifted: Roche's polatuzumab vedotin + R-CHP (Polivy plus rituximab-cyclophosphamide-doxorubicin-prednisone) won 1L DLBCL approval in 2023 on PFS [6], so the R-CHOP-only control arm in this trial is statistically valid but increasingly behind clinical practice in major markets. The confirmatory EPCORE DLBCL-1 (NCT04628494) topline (January 16, 2026) showed PFS benefit (HR 0.74) but missed OS [8] - meaningful new context for the program's regulatory trajectory.

Epcoritamab is an approved bispecific being tested in a new indication. The molecule carries accelerated approval (a regulatory pathway permitting approval based on a surrogate endpoint, with full approval contingent on a confirmatory trial demonstrating clinical benefit) for R/R DLBCL after 2+ lines (BLA 761324, May 2023) [3]. The confirmatory trial EPCORE DLBCL-1 (NCT04628494, n≈483) reported topline results in January 2026: epcoritamab beat investigator's choice salvage chemotherapy on PFS (HR 0.74, 95% CI 0.60-0.92) but did not meet statistical significance on the OS co-primary, complicating the path from accelerated to full approval [4][8]. NCT05578976 (EPCORE DLBCL-2) is a separate push into frontline DLBCL, testing epcoritamab + R-CHOP vs R-CHOP, with a primary endpoint of PFS in IPI 3-5 by IRC per Lugano criteria; enrollment target is approximately 900 patients randomized 2:1, recruitment began January 2023, and a primary readout in the 2027-2028 window is consistent with typical 1L DLBCL trial pace [5]. EPCORE FL-1 read out positive in Lancet (Falchi et al., January 2026), showing PFS benefit for epcoritamab + lenalidomide + rituximab versus lenalidomide + rituximab in R/R follicular lymphoma - a clean expansion win for the franchise [1]. EPCORE CLL-1 also reported activity in Richter transformation, a high-unmet-need population where current options are essentially salvage chemoimmunotherapy or allo-transplant (allogeneic stem cell transplant - a curative-intent procedure with significant treatment-related mortality) [2]. No additional FDA designations have been announced specifically for the 1L DLBCL program; outpatient administration data from EPCORE NHL-6 supports the subcutaneous tolerability argument that differentiates the molecule from IV competitors [7].

CD20 is a protein found almost exclusively on B cells, the immune cells that produce antibodies. In B-cell lymphomas, the cancer cells keep CD20 on their surface, which is why rituximab (an anti-CD20 antibody, approved in 1997) has anchored DLBCL treatment for nearly three decades. CD3 is the signaling complex on T cells: engage it, and the T cell activates and starts killing. Epcoritamab has two arms - one grabs CD20 on the lymphoma cell, the other grabs CD3 on a T cell that happens to be passing by. That forced contact creates a synapse: the T cell releases perforin and granzymes, the lymphoma cell dies, regardless of whether the T cell ever recognized that cancer antigen on its own. Mechanism validation is essentially complete. Blinatumomab (CD19xCD3) won approval in 2014. Glofitamab and mosunetuzumab, both CD20xCD3 bispecifics from Roche, followed for DLBCL and follicular lymphoma respectively. CAR-T products against CD19 work in the same patient populations. T-cell engagers work in B-cell malignancies. Epcoritamab's specific differentiators are (1) subcutaneous delivery vs. IV competitors, lowering chair time and enabling community administration; and (2) fixed-duration dosing - a defined treatment course (typically up to 12 cycles in the R-CHOP combination trials) rather than treat-to-progression - supported by NHL-2 long-term follow-up showing sustained remissions after treatment completion. The remaining question is whether these advantages translate in 1L, where patients have lower performance status compensation room than R/R populations.

NCT05578976 (EPCORE DLBCL-2) randomizes approximately 900 newly diagnosed DLBCL patients 2:1 to epcoritamab + R-CHOP (6 cycles, followed by 2 cycles of epcoritamab) versus R-CHOP (6 cycles, followed by 2 cycles of rituximab) [5]. Primary endpoint is PFS in the IPI 3-5 subgroup by Independent Review Committee per Lugano criteria; secondary endpoints include PFS in IPI 2-5, event-free survival, complete metabolic response, OS, and minimal residual disease negativity [5]. Recruitment began January 2023; a primary readout in 2027-2028 is plausible based on typical 1L DLBCL trial pace. R-CHOP (rituximab plus the CHOP chemotherapy regimen) has been the 1L standard since 2002, with cure rates around 60-65%. The design problem: POLARIX showed polatuzumab vedotin + R-CHP improved PFS over R-CHOP in 1L DLBCL, and that combination won FDA approval in 2023 for high-risk patients [6]. So the control arm here is fair statistically but increasingly stale clinically in the US and EU, where Pola-R-CHP has eroded R-CHOP use in high-IPI subsets - exactly the population EPCORE DLBCL-2's primary endpoint is anchored on. OS is harder to hit when 60%+ of patients are cured. The other concern: epcoritamab uses a step-up dosing schedule (priming doses of 0.16 mg and 0.8 mg, then full dose of 48 mg, typically requiring hospitalization or close monitoring during cycle 1 to manage cytokine release syndrome). This was designed for R/R patients, where CRS tolerability is paid for by lack of alternatives. In treatment-naive patients with better performance status, the step-up protocol becomes more of a consideration for both patient and physician choice, and stacking T-cell engagement onto chemotherapy-induced cytopenias creates overlapping risk windows.

Epcoritamab is FDA-approved (EPKINLY, 2023-05-19). BioCosm's model estimates a drug's first FDA approval, which has already happened here, so no probability is shown - any current trial is a new-indication study.

Efficacy risk runs through the comparator and the endpoint. R-CHOP cures roughly 60-65% of newly diagnosed DLBCL patients, so improving on that with a meaningful PFS delta is hard, and showing OS benefit is harder still; POLARIX itself never showed OS, only PFS [6]. The EPCORE DLBCL-1 January 2026 topline - PFS hit (HR 0.74), OS missed [8] - sharpens this risk: the same molecule already failed to convert PFS into OS in the confirmatory R/R setting. If EPCORE DLBCL-2 produces a PFS-only result, it doesn't translate to commercial differentiation against Pola-R-CHP or to durable payer positioning. On safety, FAERS (FDA Adverse Event Reporting System - passive postmarketing surveillance, useful for signal detection but not denominator-controlled) shows 417 cytokine release syndrome (CRS) reports and 93 immune effector cell-associated neurotoxicity syndrome (ICANS) reports across 1,167 total events, with 93.4% classified serious. Epkinly carries a boxed warning for both [3]. Adding T-cell engagement to R-CHOP creates overlapping toxicity with the chemotherapy regimen's myelosuppression, and the step-up dosing protocol adds inpatient or close-monitoring requirements that some community centers can't easily absorb. On execution, EPCORE DLBCL-1's OS miss puts the existing accelerated approval at regulatory risk - FDA may demand additional confirmatory data or accept the PFS benefit, but the franchise's foundation is less stable than it was a quarter ago [8]. Commercially, even with a positive 1L readout, Pola-R-CHP is entrenched in high-risk patients, CAR-T has moved into 2L (ZUMA-7, TRANSFORM), BTK inhibitor + bispecific combinations (e.g., ibrutinib or zanubrutinib with bispecifics) are emerging as a competitive class in R/R settings, and payer scrutiny on bispecific pricing in a frontline curative setting will be intense.

Worth watching. The catalyst stack just rearranged: EPCORE DLBCL-1 topline (January 2026) is now data, not catalyst - PFS hit, OS miss [8] - and the conversion of accelerated to full approval is now a live regulatory question rather than an assumed outcome. EPCORE FL-1's Lancet 2026 result already validated the expansion playbook in follicular lymphoma [1], so the franchise is broadening on plan. The signal to watch on EPCORE DLBCL-2 is any hint of OS benefit, not just PFS - the OS bar is what differentiates from Pola-R-CHP. Commercial context: Genmab reported nine-month 2024 Epkinly/Tepkinly net sales of USD 203M, with Q3 2024 at USD 82M, under a 50/50 ex-Japan profit split with AbbVie [9]. Peak sales construction: ~50,000 newly diagnosed DLBCL patients annually US+EU (DLBCL incidence ~8/100K US, ~3.8/100K EU); at 30% penetration in IPI 3-5 patients and a per-patient course revenue of ~$175K, frontline DLBCL contributes ~$2.6B gross (~$1.3B Genmab share). Adding R/R DLBCL, FL (post-EPCORE FL-1), Richter transformation, and earlier-line FL combinations brings the franchise to a plausible $2-3B Genmab-attributable peak, contingent on EPCORE DLBCL-2 hitting and EPCORE DLBCL-1 converting to full approval. Check back at the next ASH (December) and ASCO (June) for EPCORE DLBCL-1 full data and FDA's response, and watch Genmab and AbbVie earnings calls for guidance shifts. The Richter transformation data in Lancet Haematology 2026 [2] is the underrated wild card: a rare indication with brutal outcomes and almost no competition.